stockrow
Friday 6 November 2026
Export SOLV’s income statement to Excel — free account
Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
86.56
2.79
−3.12%
Follow SOLV
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 5 | 6 | — |
| 38.86% | 34.79% | 33.96% | 3.19% | ||
| 10.82% | 10.01% | 9.78% | 1.11% | ||
ROIC |
14.81% | 13.60% | 13.40% | 0.00% | |
Return on Tangible Assets |
75.94% | 80.45% | 87.28% | 133.33% | |
Average Days of Receivables |
51.91 | 52.13 | 62.90 | 62.20 | |
Free Cash Flow per Share |
(0.06) | (1.17) | (0.68) | 0.00 | |
Free Cash Flow |
(10.00) | (203.00) | (118.00) | 0.00 | |
Capital Expenditures |
(379.00) | (354.00) | (327.00) | (310.00) | |
| Other line items | |||||
Cash ROIC |
(0.09%) | (1.88%) | (1.12%) | 0.00% | |
Accounts Receivable Turnover |
6.90 | 7.21 | 6.19 | 6.36 | |
Accounts Payable Turnover |
5.94 | 5.88 | 5.60 | 0.00 | |
Inventory Turnover |
3.81 | 3.92 | 3.76 | 0.00 | |
Average Days of Payables |
64.73 | 66.63 | 67.94 | 0.00 | |
Days of Inventory on Hand |
100.44 | 103.81 | 100.80 | 0.00 | |
Tax Rate |
(0.09) | (0.15) | (0.15) | (0.08) | |
Research and Development Expense of Revenue |
8.88% | 8.90% | 8.71% | 8.84% | |
Selling, General and Administrative Expense of Revenue |
37.00% | 37.98% | 39.63% | 40.74% | |
Share Based Compensation of Revenue |
1.93% | 1.97% | 2.01% | 2.06% | |
Interest Coverage |
6.29 | 6.91 | 7.80 | 0.00 | |
Operating CF/Net income |
0.24 | 0.11 | 0.15 | 1.99 | |
Depreciation/Fixed assets |
0.37 | 0.32 | 0.32 | 0.00 | |
Capex/Depreciation |
(0.78) | (0.72) | (0.65) | (0.59) | |
Revenue per Share |
47.82 | 47.43 | 48.12 | 47.79 | |
Operating CF per Share |
2.12 | 0.87 | 1.21 | 1.82 | |
Capex per Share |
(2.18) | (2.03) | (1.89) | (1.81) | |
Capex to Sales |
0.05 | 0.04 | 0.04 | 0.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026